New combo therapy aims to wipe out leukemia without lifelong drugs
NCT ID NCT07564453
First seen May 07, 2026 · Last updated Jun 16, 2026 · Updated 8 times
Summary
This study tests a new treatment plan for people aged 15 to 65 with a type of blood cancer called B-cell acute lymphoblastic leukemia. The plan combines a reduced dose of chemotherapy with an immunotherapy drug called blinatumomab, followed by more chemo and possibly a stem cell transplant. The goal is to improve the chance of staying cancer-free for at least two years without needing long-term maintenance therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B ACUTE LYMPHOBLASTIC LEUKEMIA, PHILADELPHIA CHROMOSOME NEGATIVE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.